ライフサイエンスコーパス: cytomegalovirus retinitis

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ents: 2 Pneumocystis carinii pneumonia and 1 cytomegalovirus retinitis.

2 ction therapy and the time to progression of cytomegalovirus retinitis.

3 rimary outcome we studied was progression of cytomegalovirus retinitis.

4 f 188 patients with AIDS and newly diagnosed cytomegalovirus retinitis.

5 fective local therapy for AIDS patients with cytomegalovirus retinitis.

6 uent diagnoses were ocular toxoplasmosis and cytomegalovirus retinitis.

7 n, which have received FDA approval to treat cytomegalovirus retinitis and high blood cholesterol, re

8 The proportion of ADIs attributable to cytomegalovirus retinitis and Mycobacterium avium comple

9 stem cell transplantation and a case each of cytomegalovirus retinitis and pneumonitis.

10 homa control, infectious corneal ulceration, cytomegalovirus retinitis, and retinopathy of prematurit

11 tial pneumonitis, systemic fungal infection, cytomegalovirus retinitis, and tuberculosis were all les

12 nformation about patients who develop active cytomegalovirus retinitis as an immune reconstitution in

13 The treatment of cytomegalovirus retinitis (CMV-R) has improved considera

14 munodeficiency syndrome (AIDS) patients with Cytomegalovirus retinitis (CMVR) -related retinal detach

15 Advances in management of cytomegalovirus retinitis (CMVR) include laser demarcati

16 relates of immune recovery from AIDS-related cytomegalovirus retinitis (CMVR), multiparameter flow cy

17 Cytomegalovirus retinitis could be prevented by improved

18 ia, Mycobacterium avium complex disease, and cytomegalovirus retinitis) declined from 21.9 per 100 pe

19 ganciclovir (9.9 percent) had progression of cytomegalovirus retinitis during the first four weeks (d

20 as administered as the initial treatment for cytomegalovirus retinitis (group A); 17 eyes had previou

21 vir as induction therapy for newly diagnosed cytomegalovirus retinitis in 160 patients with the acqui

22 cells may also be involved in modulation of cytomegalovirus retinitis in human patients.

23 ll subsets might be used to treat or prevent cytomegalovirus retinitis in immunosuppressed human pati

24 nd effective for the long-term management of cytomegalovirus retinitis in patients with AIDS.

25 implant is effective for local treatment of cytomegalovirus retinitis in patients with the acquired

26 e an alternative method for the treatment of cytomegalovirus retinitis in patients with the acquired

27 oral candidiasis, IR, 1.2; 95% CI, 1.0-1.5; cytomegalovirus retinitis, IR, 0.5; 95% CI, 0.3-0.6; and

28 Cytomegalovirus retinitis is associated with a high abso

29 Cytomegalovirus retinitis is usually diagnosed clinicall

30 In patients with AIDS and cytomegalovirus retinitis, oral ganciclovir in conjuncti

31 Cytomegalovirus retinitis remains a major cause of illne

32 of HIV-associated ocular disease, including cytomegalovirus retinitis, the leading cause of vision l

33 Human cytomegalovirus retinitis, the most common ophthalmic in

34 For the treatment of cytomegalovirus retinitis, the sustained-release gancicl

35 irus (HIV)-infected patients with concurrent cytomegalovirus retinitis were divided into three groups

36 enty-seven patients with AIDS and unilateral cytomegalovirus retinitis were randomly assigned to one

37 Treatment and subsequent maintenance of cytomegalovirus retinitis with 20 micrograms of intravit

38 eyes of patients who received treatment for cytomegalovirus retinitis with either a ganciclovir impl

39 Treatment of unilateral cytomegalovirus retinitis with systemic ganciclovir decr

40 s photographically determined progression of cytomegalovirus retinitis within four weeks after the in

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。